|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ribeiro IL, de Medeiros JJ, Rodrigues LV,
Valenca AM and Lima Neto Ede A: Factors associated with lip and
oral cavity cancer. Rev Bras Epidemiol. 18:618–629. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Varoni EM, Lodi G and Iriti M: Ethanol
versus phytochemicals in wine: Oral cancer risk in a light drinking
perspective. Int J Mol Sci. 16:17029–17047. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mascitti M, Orsini G, Tosco V,
Monterubbianesi R, Balercia A, Putignano A, Procaccini M and
Santarelli A: An overview on current non-invasive diagnostic
devices in oral oncology. Front Physiol. 9:15102018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Polverini PJ, D'Silva NJ and Lei YL:
Precision therapy of head and neck squamous cell carcinoma. J Dent
Res. 97:614–621. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dinesh P and Rasool M: Multifaceted role
of IL-21 in rheumatoid arthritis: Current understanding and future
perspectives. J Cell Physiol. 233:3918–3928. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zuniga EI, Macal M, Lewis GM and Harker
JA: Innate and adaptive immune regulation during chronic viral
infections. Annu Rev Virol. 2:573–597. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Croce M, Rigo V and Ferrini S: IL-21: A
pleiotropic cytokine with potential applications in oncology. J
Immunol Res. 2015:6965782015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Davis MR, Zhu Z, Hansen DM, Bai Q and Fang
Y: The role of IL-21 in immunity and cancer. Cancer Lett.
358:107–114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen C, Liu X and Ren Y: Interleukin 21
treatment in a murine model as a novel potential cytokine
immunotherapy for colon cancer. Adv Clin Exp Med. 27:583–589. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li L, Ma Y, Xu Y and Maerkeya K: TIM-3
expression identifies a distinctive PD-1(+) follicular helper T
cell subset, with reduced interleukin 21 production and B cell help
function in ovarian cancer patients. Int Immunopharmacol.
57:139–146. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang LN, Cui YX, Ruge F and Jiang WG:
Interleukin 21 and its receptor play a role in proliferation,
migration and invasion of breast cancer cells. Cancer Genomics
Proteomics. 12:211–221. 2015.PubMed/NCBI
|
|
13
|
Bhatia S, Curti B, Ernstoff MS, Gordon M,
Heath EI, Miller WH Jr, Puzanov I, Quinn DI, Flaig TW,
VanVeldhuizen P, et al: Recombinant interleukin-21 plus sorafenib
for metastatic renal cell carcinoma: A phase 1/2 study. J
Immunother Cancer. 2:22014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhatt S, Sarosiek KA and Lossos IS:
Interleukin 21-its potential role in the therapy of B-cell
lymphomas. Leuk Lymphoma. 58:17–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Timmerman JM, Byrd JC, Andorsky DJ, Yamada
RE, Kramer J, Muthusamy N, Hunder N and Pagel JM: A phase I
dose-finding trial of recombinant interleukin-21 and rituximab in
relapsed and refractory low grade B-cell lymphoproliferative
disorders. Clin Cancer Res. 18:5752–5760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Katabi N and Lewis JS: Update from the 4th
edition of the world health organization classification of head and
neck tumours: What is new in the 2017 WHO blue book for tumors and
tumor-like lesions of the neck and lymph nodes. Head Neck Pathol.
11:48–54. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Head and Neck Cancer Study Group (HNCSG),
; Monden N, Asakage T, Kiyota N, Homma A, Matsuura K, Hanai N,
Kodaira T, Zenda S, Fujii H, et al: A review of head and neck
cancer staging system in the TNM classification of malignant tumors
(eighth edition). Jpn J Clin Oncol. 49:589–595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun ZP, Gong L, Huang SH, Geng Z, Cheng L
and Chen ZY: Intracellular trafficking and secretion of cerebral
dopamine neurotrophic factor in neurosecretory cells. J Neurochem.
117:121–132. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Olson B: Assays for determination of
protein concentration. Curr Protoc Pharmacol. 73:A 3A 1–A 3A 32.
2016. View
Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tangye SG and Ma CS: Regulation of the
germinal center and humoral immunity by interleukin-21. J Exp Med.
217:e201916382020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gharibi T, Majidi J, Kazemi T,
Dehghanzadeh R, Motallebnezhad M and Babaloo Z: Biological effects
of IL-21 on different immune cells and its role in autoimmune
diseases. Immunobiology. 221:357–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Ye LJ, Ren HL, Huyan T, Li J, Shi JL
and Huang QS: Multiple effects of IL-21 on human NK cells in ex
vivo expansion. Immunobiology. 220:876–888. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Romee R, Leong JW and Fehniger TA:
Utilizing cytokines to function-enable human NK cells for the
immunotherapy of cancer. Scientifica (Cairo).
2014:2057962014.PubMed/NCBI
|
|
25
|
Spolski R and Leonard WJ: Interleukin-21:
A double-edged sword with therapeutic potential. Nat Rev Drug
Discov. 13:379–395. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davis ID, Brady B, Kefford RF, Millward M,
Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard
D, et al: Clinical and biological efficacy of recombinant human
interleukin-21 in patients with stage IV malignant melanoma without
prior treatment: A phase IIa trial. Clin Cancer Res. 15:2123–2129.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim N, Cho D, Kim H, Kim S, Cha YJ,
Greulich H, Bass A, Cho HS and Cho J: Colorectal
adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to
EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. Int
J Cancer. 146:2194–2200. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Steele N, Anthony A, Saunders M, Esmarck
B, Ehrnrooth E, Kristjansen PE, Nihlen A, Hansen LT and Cassidy J:
A phase 1 trial of recombinant human IL-21 in combination with
cetuximab in patients with metastatic colorectal cancer. Br J
Cancer. 106:793–798. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dutta A, Banerjee A, Saikia N, Phookan J,
Baruah MN and Baruah S: Negative regulation of natural killer cell
in tumor tissue and peripheral blood of oral squamous cell
carcinoma. Cytokine. 76:123–130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang Q, Qiao X, Li D, Chen B, Zhang L,
Yuan C and Lin H: Expression and association of IL-21, FBXL20 and
tumour suppressor gene PTEN in laryngeal cancer. Saudi J Biol Sci.
26:2048–2051. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jin Y, Sun Z, Geng J, Yang L, Song Z, Song
H, Wang J and Tang J: IL-21 reinvigorates exhausted natural killer
cells in patients with HBV-associated hepatocellular carcinoma in
STAT1-depedent pathway. Int Immunopharmacol. 70:1–8. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seo H, Jeon I, Kim BS, Park M, Bae EA,
Song B, Koh CH, Shin KS, Kim IK, Choi K, et al: IL-21-mediated
reversal of NK cell exhaustion facilitates anti-tumour immunity in
MHC class I-deficient tumours. Nat Commun. 8:157762017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Leonard WJ, Lin JX and O'Shea JJ: The γ c
family of cytokines: Basic biology to therapeutic ramifications.
Immunity. 50:832–850. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Floros T and Tarhini AA: Anticancer
cytokines: Biology and clinical effects of interferon-α2,
interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol.
42:539–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bruce-Chwatt LJ: Declaration of helsinki.
Recommendations guiding doctors in clinical research. WHO Chron.
19:31–32. 1965.PubMed/NCBI
|
|
36
|
Woods S and McCormack P: Disputing the
ethics of research: The challenge from bioethics and patient
activism to the interpretation of the declaration of helsinki in
clinical trials. Bioethics. 27:243–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
